Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

Phase 2 Recruiting 50 enrolled University of Illinois at Chicago Huntsman Cancer Institute · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)

Timeline

Start: 2023-01-05
Primary completion: 2030-12
Completion: 2030-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Isatuximab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Lenalidomide	Other / unclassified	15 mg	Oral

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

Summary

Timeline

Drugs

Indications